Navican Raises $15M

NEW YORK (GenomeWeb) – Intermountain Healthcare spinout Navican Genomics today said it closed a $15 million Series A financing round, led by Intermountain.

The financing will go toward the commercialization and expansion of Navican’s precision cancer care offering, including the commercialization of its TheraMap solution, which leverages precision genomics, clinical analytics, and patient services for cancer management.

Navican provides genomics testing services and was spun out by Intermountain late last year. On Thursday, it and Philips announced they would offer end-to-end oncology services, leveraging TheraMap with the Philips IntelliSpace Genomics platform. 

Be the first to comment

Leave a Reply

Your email address will not be published.